Pharmaceutical people never stop innovating! In August, a batch of new drugs made great progress!

[China Pharmaceutical network industry trends] the pace of human innovation has never stopped In the field of medicine, pharmaceutical companies are also striving to use innovative technology to benefit mankind The author understands that in August, a lot of innovative drugs have made great progress, such as Huahai Pharmaceutical Co., Ltd.'s ROF theluost tablet has been temporarily approved by FDA; Hengrui Pharmaceutical Co., Ltd.'s tovaptan has been temporarily approved by FDA; Haizheng Pharmaceutical Co., Ltd.'s new Alzheimer's disease drug has been approved by FDA, etc On August 1, Zhejiang Huahai Pharmaceutical Co., Ltd issued a notice that the company received the notice from the FDA of the United States, and the brief application for new drug of the company has been approved temporarily At present, Huahai pharmaceutical has reached a settlement with the original manufacturer on legal proceedings "Pantoprazole sodium for injection" of Puli pharmaceutical has been approved for listing in Australia Recently, pantoprazole sodium for injection produced by the company has been approved for listing in Australia, Puli pharmaceutical announced This is the third international market license for the drug after Holland and Germany Due to the arrangement of the company's international market development strategy, the listing license is held by the partner aft pharmaceuticals Pty Ltd and the company is responsible for production, pril said Evergrande tovaptan was temporarily approved by the U.S FDA on August 6 Jiangsu Evergrande Pharmaceutical Co., Ltd recently announced that the company received a notice from the U.S Food and Drug Administration (FDA), and the brief new drug application (anda) of tovaptan tablets (specification: 15mg, 30mg) declared by Evergrande to the U.S FDA has been temporarily approved New Alzheimer's disease drug approved by FDA Recently, Haizheng Pharmaceutical (Hangzhou) Co., Ltd., a holding subsidiary of Zhejiang Haizheng Pharmaceutical Co., Ltd., received a notice from the U.S FDA The brief application of donepezil hydrochloride orally disintegrating tablets declared by Haizheng Hangzhou Co., Ltd to the U.S FDA has been approved, which indicates that the company has the qualification to sell the product in the U.S market and has a positive impact on the company's expansion of the U.S market On August 9, the clinical approval document for the treatment of macular degeneration by traditional Chinese medicine was issued to Tianshili sanhuangjingshiming pill Tianshili Pharmaceutical Group Co., Ltd announced that it received the approval document for clinical trial of sanhuangjingshiming pill (approval document No.: 2018l02796) approved and issued by the State Food and drug administration The product met the requirements of drug registration and was approved for clinical trial Hengrui pharmaceutical pyrrolidine was officially approved to be listed and issued the 2018 semi annual report The company's operating revenue was 7.761 billion yuan, an increase of 22.32% year-on-year; the net profit attributable to the parent company was 1.91 billion yuan, an increase of 21.4% year-on-year The R & D investment of the company has reached a new high Several heavy new drugs have entered the harvest period 19K has been approved for production Pyrrolidine is in the "approval completed - to be certified" It is reported that the product has been officially approved for listing, and three new drugs of category 1 such as PD-1 have been reported for production Olapari, a new targeted drug for ovarian cancer, was approved in China as a new targeted drug for AstraZeneca Olaparib is also a new targeted drug for ovarian cancer listed in China Olapalin belongs to PARP inhibitor, which is a new mechanism of anticancer drug specially designed for DNA repair defects of cancer cells It is one of the hot new targeted drugs in recent years.